pre-IPO PHARMA

COMPANY OVERVIEW

CERo Therapeutics, Inc. is a biopharmaceutical company pioneering a new class of cell-based therapies that combine attributes of the innate and adaptive arms of the immune system into single T cells. The integrated approach draws on recent advances in synthetic and T-cell biology with the intent to improve upon and optimize cell therapy to increase the curative potential and safety profile of current approaches. CERo is advancing a pipeline of engineered CER T-cell products directed against hematologic malignancies and solid tumors. To learn more about the company and its science, please visit www.cero.bio.


LOCATION


THERAPEUTIC AREAS


WEBSITE

None


CAREER WEBSITE

None


SOCIAL MEDIA


INVESTORS


PRESS RELEASES


Jun 5, 2023

CERo Therapeutics, Inc. and Phoenix Biotech Acquisition Corp. Announce Merger Agreement to Create Public Company Advancing the Development of Next Generation Engineered T Cell Therapeutics


May 2, 2022

CERo Therapeutics’ Multifunctional CER T Cells Synergize with Standard-of-Care Small Molecule Anti-Tumor Inhibitors Across Hematologic and Solid Tumor Models


Nov 12, 2021

CERo Therapeutics’ Novel Chimeric Engulfment Receptor T Cells Exhibit Multifunctional Properties and Enhanced Tumor Killing


Apr 15, 2021

CERo Therapeutics Expands Leadership Team with Experts in Cell Therapy Development


For More Press Releases


Google Analytics Alternative